[go: up one dir, main page]

MX2015008481A - Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a. - Google Patents

Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.

Info

Publication number
MX2015008481A
MX2015008481A MX2015008481A MX2015008481A MX2015008481A MX 2015008481 A MX2015008481 A MX 2015008481A MX 2015008481 A MX2015008481 A MX 2015008481A MX 2015008481 A MX2015008481 A MX 2015008481A MX 2015008481 A MX2015008481 A MX 2015008481A
Authority
MX
Mexico
Prior art keywords
compounds
heterobicyclo
quinazolin
triazolo
ami
Prior art date
Application number
MX2015008481A
Other languages
English (en)
Other versions
MX370017B (es
Inventor
Dong Xiao
Andrew Stamford
Paul Tempest
Xianhai Huang
Rongze Kuang
Jae-Hun Kim
Yeon-Hee Lim
Junying Zheng
Walter Won
Amjad Ali
Edward Metzger
Timothy J Henderson
Younong Yu
Heping Wu
Nicolas Zorn
Christopher Boyce
Michael Man-Chu Lo
Pauline Ting
Gioconda V Gallo
Qiaolin Deng
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2015008481A publication Critical patent/MX2015008481A/es
Publication of MX370017B publication Critical patent/MX370017B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describen compuestos de fórmula GI: (ver Fórmula) en donde "RG3" "Rd1", a "Rd4","n","m","p", "W","X", "Y" y "Z" son como se definen en la presente, cuyos compuestos son antagonistas del receptor A2A; también se describen en la presente usos de los compuestos descritos en la presente como antagonistas del receptor A2A en el tratamiento potencial o prevención de trastornos y enfermedades neurológicas en las cuales están involucrados los receptores A2A; en la presente también se describen composiciones farmacéuticas que comprenden estos compuestos y usos de estas composiciones farmacéuticas.
MX2015008481A 2012-12-28 2013-12-20 Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a. MX370017B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/087865 WO2014101120A1 (en) 2012-12-28 2012-12-28 Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
PCT/CN2013/076853 WO2014101373A1 (en) 2012-12-28 2013-06-06 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder
PCT/US2013/076781 WO2014105666A1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Publications (2)

Publication Number Publication Date
MX2015008481A true MX2015008481A (es) 2015-09-23
MX370017B MX370017B (es) 2019-11-28

Family

ID=51019745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008481A MX370017B (es) 2012-12-28 2013-12-20 Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.

Country Status (22)

Country Link
US (2) US9708347B2 (es)
EP (1) EP2945632B1 (es)
JP (1) JP6306049B2 (es)
KR (1) KR102165113B1 (es)
AU (1) AU2013370977B2 (es)
BR (1) BR112015015468B8 (es)
CA (1) CA2896056C (es)
CY (1) CY1120258T1 (es)
DK (1) DK2945632T3 (es)
ES (1) ES2667477T3 (es)
HR (1) HRP20180678T1 (es)
HU (1) HUE037950T2 (es)
LT (1) LT2945632T (es)
ME (1) ME03034B (es)
MX (1) MX370017B (es)
NO (1) NO2945632T3 (es)
PL (1) PL2945632T3 (es)
PT (1) PT2945632T (es)
RS (1) RS57162B1 (es)
RU (2) RU2671628C2 (es)
SI (1) SI2945632T1 (es)
WO (3) WO2014101120A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
US10688082B2 (en) 2015-06-11 2020-06-23 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
WO2017008205A1 (en) * 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
WO2017034994A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
WO2017034990A1 (en) * 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
EP3394061B1 (en) 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017107087A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018130184A1 (zh) 2017-01-13 2018-07-19 江苏恒瑞医药股份有限公司 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用
WO2018153373A1 (zh) 2017-02-27 2018-08-30 贝达药业股份有限公司 Fgfr抑制剂及其应用
RU2764655C2 (ru) 2017-03-16 2022-01-19 Цзянсу Хэнжуй Медицин Ко., Лтд. ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
ES2927086T3 (es) * 2017-09-28 2022-11-02 Cstone Pharmaceuticals Suzhou Co Ltd Derivado de anillo condensado como inhibidor del receptor A2A
WO2019118313A1 (en) 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
EP3750891A4 (en) 2018-02-06 2021-08-11 Jiangsu Hengrui Medicine Co., Ltd. PYRAZOLO [1,5-A] [1,3,5] TRIAZINE-2-AMINE DERIVATIVE, METHOD OF PREPARATION AND MEDICAL USE
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP2022511778A (ja) 2018-11-30 2022-02-01 メルク・シャープ・アンド・ドーム・コーポレーション アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
JOP20210116A1 (ar) 2018-11-30 2023-01-30 Merck Sharp & Dohme مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
ES2944511T3 (es) 2019-03-26 2023-06-21 Novel Pharma Inc Derivado de GnRH que se une a ácido graso de acción prolongada y composición farmacéutica que comprende el mismo
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022020552A1 (en) * 2020-07-24 2022-01-27 Merck Sharp & Dohme Corp. Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
WO2022020550A1 (en) * 2020-07-24 2022-01-27 Merck Sharp & Dohme Corp. Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
CN112159411A (zh) * 2020-10-15 2021-01-01 南京工业大学 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
EP0181282A1 (de) * 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) * 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
US5736564A (en) 1994-06-20 1998-04-07 Smithkline Beecham Corporation Endothelin receptor antagonists
US5571775A (en) * 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US5929106A (en) 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
SK287748B6 (sk) * 2000-05-26 2011-08-04 Schering Corporation Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
EP1293029A1 (en) * 2000-06-20 2003-03-19 Alexander Ellison Rees Electrical drive line
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
CA2493637A1 (en) 2002-07-25 2004-02-12 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
NZ540493A (en) * 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
EP1633756B1 (en) * 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
TWI355381B (en) * 2003-04-23 2012-01-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
MX2009000104A (es) 2006-06-26 2009-01-23 Schering Corp Antagonistas del receptor de adenosina a2a.
US20090062253A1 (en) 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
EP2509983B1 (en) * 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Also Published As

Publication number Publication date
WO2014105666A1 (en) 2014-07-03
CY1120258T1 (el) 2019-07-10
BR112015015468B8 (pt) 2023-04-25
PL2945632T3 (pl) 2018-07-31
US10011615B2 (en) 2018-07-03
HUE037950T2 (hu) 2018-09-28
DK2945632T3 (en) 2018-05-22
RU2018136104A3 (es) 2022-04-05
KR102165113B1 (ko) 2020-10-13
BR112015015468B1 (pt) 2021-10-26
US20170197991A1 (en) 2017-07-13
JP2016504363A (ja) 2016-02-12
EP2945632B1 (en) 2018-03-07
JP6306049B2 (ja) 2018-04-04
RS57162B1 (sr) 2018-07-31
PT2945632T (pt) 2018-05-22
US9708347B2 (en) 2017-07-18
EP2945632A4 (en) 2016-09-14
EP2945632A1 (en) 2015-11-25
BR112015015468A2 (pt) 2017-07-11
ME03034B (me) 2018-10-20
SI2945632T1 (en) 2018-05-31
HRP20180678T1 (hr) 2018-06-01
AU2013370977A1 (en) 2015-07-09
ES2667477T3 (es) 2018-05-11
US20150361098A1 (en) 2015-12-17
WO2014101373A1 (en) 2014-07-03
RU2671628C2 (ru) 2018-11-06
RU2018136104A (ru) 2018-11-21
WO2014101120A1 (en) 2014-07-03
NO2945632T3 (es) 2018-08-04
KR20150100879A (ko) 2015-09-02
RU2015131148A (ru) 2017-02-03
CA2896056C (en) 2020-11-10
MX370017B (es) 2019-11-28
AU2013370977B2 (en) 2017-12-14
LT2945632T (lt) 2018-05-25
CA2896056A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
MX370017B (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IN2015KN00414A (es)
TN2015000250A1 (en) Novel benzimidazole derivatives as ep4 antagonists
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
IN2014DN07384A (es)
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
AU2011234398A8 (en) Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
WO2013163190A8 (en) Dna-pk inhibitors
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX2013004298A (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2014006433A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2.
AU2012357747A8 (en) TRPM8 antagonists
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.

Legal Events

Date Code Title Description
FG Grant or registration